Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group

International Journal of STD and AIDS

Volumn 23, Issue 3, 2012, Pages 201-206

  Stekler, J D ^a,b   Wellman, R ^b   Holte, S ^b,c   Maenza, J ^a   Stevens, C E ^a   Corey, L ^b,c   Collier, A C ^a,b  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

Author keywords

Antiretroviral therapy; PHI; Primary HIV infection; Seroconversion

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BACTERIAL INFECTION; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMBINATION ANTIRETROVIRAL THERAPY; COMORBIDITY; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; DEATH; DISEASE COURSE; DISEASE SEVERITY; DRUG INDICATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIMARY INFECTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; THERAPY DELAY; TREATMENT OUTCOME; UNITED STATES; VIRUS INFECTION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84860893841     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.011178     Document Type: Article

References (40)

1. Malhotra U, Berrey MM, Huang Y, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000;181:121-31
2. Pilcher CD, Shugars DC, Fiscus SA, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 2001;15:837-45
3. Karlsson AC, Birk M, Lindback S, Gaines H, Mittler JE, Sonnerborg A. Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution. AIDS Res Hum Retroviruses 2001;17:409-16
4. Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005;191:1410-18
5. Desquilbet L, Goujard C, Rouzioux C, et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004;18:2361-69
6. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006;194:725-33
7. Streeck H, Jessen H, Alter G, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 2006;194:734-39
8. Steingrover R, Schellens I, Verbon A, et al. Temporary ART during primary HIV-1 infection lowers the viral set-point: the prospective, randomized Primo-SHM Study. Paper presented at: Boston: 15th Conference on Retroviruses and Opportunistic Infections, 2008 [abstract #698b]
9. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl Jo Med 1995;333:408-13
10. Niu MT, Bethel J, Holodniy M, Standiford HC, Schnittman SM. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. J Infect Dis 1998;178:80-91
11. Kinloch-de Loes S, Perneger TV. Primary HIV infection: follow-up of patients initially randomized to zidovudine or placebo. J Infect 1997;35:111-16
12. Hoen B, Dumon B, Harzic M, et al. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. J Infect Dis 1999;180:1342-46
13. Smith D, Berrey MM, Robertson M, et al. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis 2000;182:950-54
14. Berrey MM, Schacker T, Collier AC, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001;183:1466-75
15. Fidler S, Oxenius A, Brady M, et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002;16:2049-54
16. Lillo FB, Ciuffreda D, Veglia F, et al. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. AIDS 1999;13:791-96
17. Kassutto S, Maghsoudi K, Johnston MN, et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 2006;42:1024-31
18. Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K. The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS 2008;22:2441-50
19. Steingrover R, Pogany K, Fernandez Garcia E, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 2008;22:1583-88
20. Koegl C, Wolf E, Hanhoff N, et al. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 2009;14:277-83
21. Steingrover R, Garcia EF, van Valkengoed IG, et al. Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. AIDS Res Hum Retroviruses 2010;26:379-87
22. Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 2012;205:87-96
23. Fidler S, Ewings F, Porter K, et al. A comparison of HIV viral rebound following ART cessation in primary and chronic HIV infection. Paper presented at: San Francisco: 17th Conference on Retroviruses and Opportunistic Infections, 2010 [#474]
24. Fidler S. The effect of short-course antiretroviral therapy in primary HIV infection: final results from an international randomised controlled trial; SPARTAC. Italy: Sixth IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2011 [abstract #WELBX06]2011
25. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257-64
26. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998;128:613-20
27. Stekler J, Sycks BJ, Holte S, et al. HIV dynamics in seminal plasma during primary HIV infection. AIDS Res Hum Retroviruses 2008;24:1269-74
28. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-26
29. Zala C, Salomon H, Ochoa C, et al. Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. J Acquir Immune Defic Syndr 2002;29:368-73
30. Blanckenberg DH, Wood R, Horban A, et al. Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects. AIDS 2004;18:631-40
31. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19
32. Mandell GL. Mandell, Bennett, & Dolin: Principles and Practice of Infectious Diseases. 6th edn. Philadelphia: Elsevier, 2005
33. Clements M, Law M, Pedersen C, Kaldor J. Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data. HIV Med 2003;4:332-37
34. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 1):S5-14
35. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Clin Infect Dis 1995;21(Suppl 1):S1-11
36. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005;352:1873-83
37. Stekler J, Swenson PD, Wood RW, Handsfield HH, Golden MR. Targeted screening for primary HIV infection through pooled HIV-RNA testing in men who have sex with men. AIDS 2005;19:1323-25
38. Patel P, Klausner JD, Bacon OM, et al. Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr 2006;42:75-79
39. Priddy FH, Pilcher CD, Moore RH, et al. Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr 2007;44:196-202
40. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505 (Accepted 12 November 2011)